Literature DB >> 16686706

Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.

Bradford A Nelson1, Scott B Shappell, Sam S Chang, Nancy Wells, Scott B Farnham, Joseph A Smith, Michael S Cookson.   

Abstract

UNLABELLED: Authors from the USA sought to establish the relationship between tumour volume, pathological stage and outcomes after radical prostatectomy. In a large series of patients they found that tumour volume was correlated directly with pathological stage, and that it was independently correlated with PSA recurrence. The authors suggested that tumour volume had a potential use for prognostication in patients undergoing radical prostatectomy. Two papers, one from the USA and one from Germany, advise a re-staging TUR in patients with superficial bladder cancer who are at high risk of early tumour progression. In a large series of patients they found that residual tumour after initial resection was commoner than might be expected, and that the second resection indicated the way to earlier radical treatment and a better prognosis.
OBJECTIVE: To establish the relationship between tumour volume (TV), pathological stage and outcome after radical prostatectomy (RP), as TV is theoretically an important variable in prostate cancer pathology, but to date it has not been routinely reported and its independent prognostic significance is not well defined. PATIENTS AND METHODS: The study included 431 consecutive patients undergoing RP for clinically localized cancer, from January 2000 to January 2002, who had a pathological examination of totally submitted whole-mount processed RP specimens. In addition to Gleason grade, tumour stage and margin assessment by standard techniques, TV was determined by digital planimetry. The total TV or index TV, for cases with obvious discrete separate tumours, were correlated with pathological stage and prostate-specific antigen (PSA) recurrence.
RESULTS: The mean (range) follow-up was 25.4 (6-51) months, and the mean TV for all patients was 3.28 (0.4-38.8) mL. There was a direct correlation between TV and pathological stage (P < 0.001). The TV for organ-confined and extraprostatic disease was 2.09 and 6.02 mL, respectively (P < 0.001). In a multivariate analysis, TV was an independent predictor of PSA recurrence (P = 0.04). The mean TV for patients with PSA recurrence vs no recurrence was 6.8 and 2.6 mL, respectively (P < 0.001).
CONCLUSION: TV correlates directly with pathological stage in RP specimens; furthermore, it is independently correlated with PSA recurrence. TV has potential use for prognostication in patients undergoing RP, and may be combined with other well established clinical variables to aid in predicting outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686706     DOI: 10.1111/j.1464-410X.2006.06148.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  34 in total

1.  Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods.

Authors:  Ian M Thompson; Shady Salem; Sam S Chang; Peter E Clark; Rodney Davis; S Duke Herrell; Yakup Kordan; Roxelyn Baumgartner; Sharon Phillips; Joseph A Smith; Michael S Cookson; Daniel A Barocas
Journal:  World J Urol       Date:  2010-11-16       Impact factor: 4.226

Review 2.  Image guidance in the focal treatment of prostate cancer.

Authors:  Anthony N Hoang; Dmitry Volkin; Nitin K Yerram; Srinivas Vourganti; Jeffrey Nix; W Marston Linehan; Bradford Wood; Peter A Pinto
Journal:  Curr Opin Urol       Date:  2012-07       Impact factor: 2.309

3.  Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis.

Authors:  Yang Meng; He Li; Peng Xu; Jia Wang
Journal:  Int J Clin Exp Med       Date:  2015-12-15

4.  Biochemical outcome of small-volume or insignificant prostate cancer treated with radical prostatectomy in Japanese population.

Authors:  Yasuhiro Hashimoto; Akiko Okamoto; Atsushi Imai; Tohru Yoneyama; Shingo Hatakeyama; Takahiro Yoneyama; Takuya Koie; Noritaka Kaminura; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2011-06-16       Impact factor: 3.402

5.  The prognostic significance of percentage of tumour involvement according to disease risk group in men treated with radical prostatectomy.

Authors:  Jong Jin Oh; Sang Cheol Lee; Chang Wook Jeong; Cheol Yong Yoon; Seong Jin Jeong; Sung Kyu Hong; Seok-Soo Byun; Yoon Kwan Rho; Gheeyoung Choe; Sang Eun Lee
Journal:  Asian J Androl       Date:  2011-09-26       Impact factor: 3.285

6.  Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy.

Authors:  Georg Müller; Malte Rieken; Gernot Bonkat; Joel Roman Gsponer; Tatjana Vlajnic; Christian Wetterauer; Thomas C Gasser; Stephen F Wyler; Alexander Bachmann; Lukas Bubendorf
Journal:  Virchows Arch       Date:  2014-08-17       Impact factor: 4.064

7.  In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence.

Authors:  Yujiro Ito; Emily A Vertosick; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; Sahussapont J Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

8.  Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients.

Authors:  Chinonyerem Okoro; Arvin K George; M Minhaj Siddiqui; Soroush Rais-Bahrami; Annerleim Walton-Diaz; Nabeel A Shakir; Jason T Rothwax; Dima Raskolnikov; Lambros Stamatakis; Daniel Su; Baris Turkbey; Peter L Choyke; Maria J Merino; Howard L Parnes; Bradford J Wood; Peter A Pinto
Journal:  J Endourol       Date:  2015-07-23       Impact factor: 2.942

9.  Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15 mm the best threshold?

Authors:  Julie Y An; Stephanie A Harmon; Sherif Mehralivand; Marcin Czarniecki; Clayton P Smith; Julie A Peretti; Bradford J Wood; Peter A Pinto; Peter L Choyke; Joanna H Shih; Baris Turkbey
Journal:  Abdom Radiol (NY)       Date:  2018-12

Review 10.  Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?

Authors:  Hashim Uddin Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.